News | Ventricular Assist Devices (VAD) | September 18, 2015

SynCardia Systems Issues Class I Recall of Freedom Driver System

Part failure on drive mechanism for Total Artificial Heart could cause device to stop pumping, resulting in serious injury or death

Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

September 18, 2015 — SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total Artificial Heart (TAH-t) on Aug. 6, 2015. The recall focused on a specific part of the Freedom Driver drive mechanism that the company said may fail and cause the device to stop pumping.

The SynCardia TAH-t is a mechanical replacement for a patient’s heart, used in patients at risk of imminent death from heart failure who are waiting for a heart transplant. It is a pump that is implanted into the chest to replace the bottom half of a patient’s heart (left and right ventricles). The device is sewn to the remaining top half of the patient’s heart (atria). The Freedom Driver system is attached to the TAH-t pump and operates and monitors the device.

SynCardia noted that patients do not receive any advance warning that the device may fail. If it does fail, a red light located in the center of the driver, toward the top, will stay red and a loud continuous alarm will sound.

However, if the Freedom Driver stops pumping, the patient will lose consciousness almost immediately, which means that the warning light and alarm may not be helpful. The patient will likely experience serious injury or death if not immediately switched to a backup driver by a caregiver.

In the Urgent Medical Device Recall Letter, SynCardia told customers they would notify all hospitals that have the affected drivers — in lot numbers 85978 (serial numbers 85978-001 through 85978-040) and 85979 (Serial Numbers 85979-001 through 85979-040) — and replace the drivers with new ones. Additionally, SynCardia informed customers to:

  • Notify any patients with an affected device and exchange the driver;
  • A SynCardia representative will assist with replacement and return of the product; and
  • Return affected Freedom Drivers and complete the Recall Acknowledgement and Receipt Form attached to the letter.

For more information: www.fda.gov/medwatch

Related Content

Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new...
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in...
Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical...
Overlay Init